Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

Study Summary

The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.